Literature DB >> 22020304

Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.

Franky Baatz1, Daniel Struck, Morgane Lemaire, Sebastien De Landtsheer, Jean-Yves Servais, Vic Arendt, Jean-Claude Schmit, Danielle Perez Bercoff.   

Abstract

Entry of Human Immunodeficiency Virus type 1 (HIV-1) into target cells is mediated by the CD4 receptor and a coreceptor, CCR5 or CXCR4. Maraviroc interferes with HIV entry by binding the CCR5 coreceptor. Virological failure to maraviroc-containing regimens can occur through the emergence of resistance, or through tropism evolution and broadened coreceptor usage. In the latter case, the physiological relevance of minority strains is a major concern. Here we report a retrospective analysis of coreceptor-usage and evolution based on 454-ultra-deep-sequencing of plasma and Peripheral Blood Mononuclear Cell (PBMC)-derived envelope V3-loops, accounting for coreceptor usage, from a patient who failed a maraviroc-containing regimen through the emergence of X4 strains. The X4 maraviroc-escape variant resulted from recombination between a long time archived proviral sequence from 2003 (5'-portion, including the V3-loop) and the dominant R5 strains circulating in plasma at the time of maraviroc-treatment initiation (3'-portion). Phylogenetic analyses and BEAST modeling highlighted that an early diverse viral quasispecies underwent a severe bottleneck following reinitiation of HAART and repeated IL-2 cycles between 1999 and 2001, leading to the transient outgrowth and archiving of one highly homogeneous X4 population from plasma, and to the expansion in plasma of one PBMC-derived R5 strain. Under maraviroc selective pressure, the early, no longer detectable X4 strains archived in PBMC were partially rescued to provide X4-determinants to the main circulating strain.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020304     DOI: 10.1016/j.antiviral.2011.10.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

2.  Clinical implications of HIV-1 minority variants.

Authors:  Jonathan Z Li; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2013-02-27       Impact factor: 9.079

3.  Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data.

Authors:  Niko Beerenwinkel; Huldrych F Günthard; Volker Roth; Karin J Metzner
Journal:  Front Microbiol       Date:  2012-09-11       Impact factor: 5.640

4.  Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing.

Authors:  Guinevere Q Lee; Luke C Swenson; Art F Y Poon; Jeffrey N Martin; Hiroyu Hatano; Steven G Deeks; P Richard Harrigan
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

5.  Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNA.

Authors:  Hiroshi Kotani; Koji Sudo; Naoki Hasegawa; Hiroshi Fujiwara; Tomohisa Hayakawa; Osamu Iketani; Masaya Yamaguchi; Mayumi Mochizuki; Satoshi Iwata; Shingo Kato
Journal:  J Pharm Health Care Sci       Date:  2016-11-09

Review 6.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

7.  Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

Authors:  Alejandro Gonzalez-Serna; Miguel Genebat; Ezequiel Ruiz-Mateos; Manuel Leal
Journal:  Drug Des Devel Ther       Date:  2016-01-18       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.